Pharma News
Blenkinsopp Pharma gets a Weblog
Keep up with current events at the Blenkinsopp Pharma Consultancy Weblog.
Chloramphenicol eye drops switch from POM to P
This switch was approved in June 2005. I am delighted to have been a member of the Galpharm team that facillitated this switch.
more … (60kB PDF).
BMA Report on OTC Medication
Alison co-authors a comprehensive BMA report on OTC medication.
more … (255kB PDF).
POM to P to PIL – The UK agenda for the EU self-care revolution
From the March 2005 edition, Regulatory Rapporteur covers Rx to OTC
switching and the new EU requirement for “user-testing” of Patient
Information Leaflets (PILs).
more … (725kB PDF).
I am delighted to introduce Professor Alison Blenkinsopp to BPC as Managing Partner.
Alison is Professor of the Practice of Pharmacy at Keele University's Department of Medicines Management. She has researched and written widely on the management of minor illness, particularly by pharmacists and nurses. Recent publications have included a series of articles for nurse prescribers on managing minor illness, and the 5th edition of "Symptoms in the Pharmacy". She is currently working on a book for the public on managing minor illness. Alison is one of the academic advisers to the Joining Up Self Care project. She led the research on patient feedback in the recently completed community pharmacy medicines management study. Alison was a member of the Committee on Safety of Medicines for the last six years and continues to sit on the BNF Formulary Committee.
John has been appointed a Non Executive Director of LUTO Research Ltd.
LUTO (Leeds University Testing Organisation) is a newly established consumer information testing company, geared towards enabling UK pharma companies to meet the new user-testing requirements for medicine information leaflets.
Our goal is to work with pharma companies to develop and test medicine information leaflets to meet the legislative requirements of the Medicines and Healthcare products Regulatory Agency (MHRA), and allow patients to safely and effectively use the relevant medicines. This is delivered using high level expertise from within the Faculty of Medicine and Health at the University of Leeds, based on associated academic research, and input into policy and practice in the area of consumer medicines information in the UK and internationally.
John in the News
John makes the headlines in the latest issue of Pharmafocus; the subject of the POM to P revolution.
Click on the cover for a closer look.
Zocor Heart Pro (simvastatin 10mg) launched in the UK
This exciting product has now been launched in the UK (July 29th 2004).
I am delighted to be part of the team that has produced the worlds first OTC statin. For more information please feel free to contact me.
Omeprazole goes from POM to P in the UK
Omeprazole has been launched as a Pharmacy (P) medicine in the UK as both a brand (Zanprol, by GSK) and as a number of generic products. The switch was instigated by Galpharm. I am delighted to be part of the team that facilitated this important POM to P switch.
The most interesting claim that Zanprol makes is: Taken once daily, Zanprol can provide relief from heartburn and, after treatment, can give weeks of remission from recurrent attacks.
To find out more about POM to P, see this document (112kB pdf file) and see the Zanprol official product information and promotion here.
John Blenkinsopp